UK pharmaceutical giant AstraZeneca has admitted that its Covid-19 vaccine can lead to a rare side effect known as Thrombosis with Thrombocytopenia Syndrome (TTS). This acknowledgment comes amid a lawsuit alleging severe harm and deaths caused by the vaccine, according to The Telegraph.

TTS, also known as vaccine-induced immune thrombotic thrombocytopenia (VITT), is an exceptionally rare condition characterized by the formation of blood clots and low platelet counts.

AstraZeneca, in collaboration with the University of Oxford, developed the vaccine and is currently facing legal action from victims and their families. One such case involves Jamie Scott, who suffered a blood clot after vaccination, resulting in lasting brain injury. Despite AstraZeneca initially disputing the connection between the vaccine and TTS, they later admitted in a legal document that the vaccine can, in rare cases, cause TTS, although the causal mechanism is unknown.

Victims and their families, including Kate, Scott's wife, demand an apology and fair compensation. Kate sees AstraZeneca's admission as progress after years of battling. The link between TTS and the AstraZeneca Covid-19 vaccine was established post-rollout, with researchers identifying a connection between the vaccine and VITT. Fifty-one cases have been filed in the High Court, with victims seeking damages exceeding £100 million.

AstraZeneca, while expressing sympathy for those affected, emphasizes its commitment to patient safety and adherence to strict regulatory standards. The company collaborated with the Serum Institute of India to supply the vaccine to the Indian Government.